Should drug companies be allowed to talk directly to patients?BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7402.1302 (Published 12 June 2003) Cite this as: BMJ 2003;326:1302
- Trevor Jones (email@example.com), director general1
- 1 ABPI, London SW1A 2DY
Increasingly, patients have been seeking to learn more about their health and about treatments available. A symptom of the demand for this greater awareness and choice has been the growth of patient organisations. They provide information—often in great detail—to patients and therefore require a full understanding of, and information about, the diseases in which they specialise and the appropriate treatments. But they do not have the same level of information about medicines as a manufacturer.
Until now, other than through patient information leaflets, legal restrictions have made it difficult for pharmaceutical manufacturers to provide information to patients about the medication they take. But patient information leaflets—contained in medicine packs—have essentially become part of the regulatory dossier and, in many cases, cannot practicably provide comprehensive information about medicines to patients. Nor do patients, carers, and the public have direct access …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial